Printer Friendly

CURATIVE TECHNOLOGIES ANNOUNCES PATENT ALLOWANCE

 CURATIVE TECHNOLOGIES ANNOUNCES PATENT ALLOWANCE
 EAST SETAUKET, N.Y., May 12 /PRNewswire/ -- Curative Technologies,


Inc. (NASDAQ: CURE) today announced the allowance by the United States Patent and Trademark Office of a broad patent application covering the use of its Platelet Derived Wound Healing Factors. The claims in the patent cover both the use of Procuren(R) which is an autologous product that is currently on the market as well as the homologous product which is in the development phase.
 "The Company has been actively pursuing patent protection for these products and is gratified by the broad claims that have been allowed by the Patent Office," said Russell B. Whitman, chairman, president and CEO. "These claims parallel the claims which have been allowed by the European Patent Office and which the company expects to be published in the near future."
 The company believes that the patents which have been allowed by the U.S. Patent Office, the European Patent Office as well as the patent offices in a number of additional countries will enable Curative Technologies to maintain a proprietary position with respect to its core Platelet Releasate technology in the area of wound healing.
 Curative Technologies, Inc. is a biopharmaceutical company engaged in the research, development, production and marketing of therapeutic products utilizing naturally occurring human growth factors. The company's first product, Procuren, is a topical therapeutic which promotes wound healing and is produced from a patient's own blood. Procuren is sold through Wound Care Centers(R), which are cooperative ventures with selected hospitals.
 -0- 5/12/91
 /CONTACT: John C. Prior, chief financial officer of Curative Technologies, 516-689-7000; Anthony J. Russo, or Susan A. Noonan of Noonan/Russo Communications, 212-979-9180, for Curative Technologies/
 (CURE) CO: Curative Technologies, Inc. ST: New York IN: MTC SU:


SH-DB -- NY084 -- 9270 05/12/92 15:41 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 12, 1992
Words:304
Previous Article:AMAX GOLD BOARD APPROVES DIVIDEND
Next Article:TRAVEL SOUTH MAGAZINE FINDS FAVORITE FISHIN' HOLES
Topics:


Related Articles
CURATIVE TECHNOLOGIES ANNOUNCES WITHDRAWAL OF REGISTRATION STATEMENT FOR PUBLIC OFFERING
CURATIVE TECHNOLOGIES ANNOUNCES SECOND QUARTER RESULTS
CURATIVE TECHNOLOGIES, INC. ANNOUNCES FOURTH QUARTER AND YEAR END RESULTS
CURATIVE TECHNOLOGIES, INC. ANNOUNCES SECOND QUARTER RESULTS
CURATIVE TECHNOLOGIES, INC. ANNOUNCES FOURTH QUARTER AND YEAR END RESULTS
Biosyn receives notice of allowance for key patent addition to C31g technology platform.
ENZO BIOCHEM GETS NEW PATENT ALLOWANCES IN U.S/CANADA.
Curative Health Services Announces Sale of Procuren(R) Operations.
Curative Health Services Completes Sale of Procuren(R) Operations.
Vitro's cell immortalization patent allowed.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters